Roche Holdings AG has decided to terminate its collaboration agreement with Blueprint Medicines Corporation for strategic reasons, allowing Blueprint Medicines to regain global commercialization and development rights to Gavreto (pralsetinib), except in Greater China. The termination will be effective in 12 months. Blueprint Medicines plans to explore options to advance and simplify the continued global commercialization and development of Gavreto, which was approved by the FDA for three indications in lung and thyroid cancer settings. The company anticipates no impact on its 2023 revenue guidance and expects its current cash position and future product revenues to enable it to achieve a self-sustainable financial profile.
Beyond the Scrubs: Understanding Healthcare Providers as People for Increased Engagement
March 28th 2024The benefits of adopting a humanized approach to healthcare provider marketing extend across the healthcare spectrum, enhancing engagement rates, brand loyalty, and marketing ROI, while also driving better outcomes for patients.
Transforming Cancer Care: Data, AI, and Patient-Centered Care
July 20th 2023Join us as Mohit Manrao, SVP and head of US oncology at AstraZeneca, shares his patient-centered approach to transforming cancer care, bridging the gap between innovative science and tangible patient outcomes across all populations on a global scale.